Browsing the "CASMI Views" Category

“We are gradually going to move away from fully fledged HTAs towards more European collaboration.”

richard Bergstrom

National associations throughout Europe are engaging with governments in a whole new way. At a recent Eyeforpharma event, Richard Bergstrom, Director General of EFPIA, spoke about: – How the regulatory model is changing – The benefits of sharing expectations and the strengths and weaknesses of company data with regulators, payers and patients [...]

August 13, 2014 Andrea Hodgetts CASMI Views 0

Putting Patients at the Heart of Medical Innovation


It’s time that we truly put patients at the heart of medical innovation. When I say that, I don’t mean adding a token patient to a conference speaker panel or ‘box ticking’ that a pharmaceutical company has consulted a patient group. What I mean is that we need to completely [...]

June 10, 2014 Andrea Hodgetts CASMI Views 0

CASMI Fellow Speaks about ‘Patient Participation in Melanoma Clinical Research’

144 09 070 RNTNEH Prof Shak Sayeed 1407_WEB_edit

CASMI Associate Fellow Dr Sarah Garner spoke at the Joint M-icab/ESO Conference in Brussels last weekend. Upon a joint invitation from m-icab, (Melanoma Independent Community Advisory Board), and ESO, (European School of Oncology) about 90 stakeholders – Melanoma patients and advocates, clinicians, representatives from the regulatory and Health Technology Assessment [...]

April 4, 2014 Andrea Hodgetts CASMI Views 0

Podcast: Reaching a Personalized Medicine Milestone

non-slider CASMI_graphic_9

With the recent news that Illumina’s latest sequencers have broken the $1,000 genome barrier, there’s great anticipation about the acceleration of personalized medicine. The Burrill Report spoke to Ed Abrahams, president of the Personalized Medicine Coalition, about the significance of the milestone, the move of whole genome sequencing to the [...]

February 4, 2014 Andrea Hodgetts CASMI Views 0

Tufts study: Data suggest breakthrough therapy designation meets goals


Nearly 18 months after its launch by the FDA, the breakthrough therapy designation (BTD) is showing the potential to meet the agency’s stated goal of speeding the development and review of drugs that show early evidence of offering substantial improvement over existing therapies on a clinically significant endpoint. By approving [...]

February 4, 2014 Andrea Hodgetts CASMI Views 0

Podcast: Pharma Faces Shrinking Returns from Innovation

burril report

The biggest pharmaceutical companies are successfully bringing new products to market, but are struggling with diminishing returns on investment, according to a new report from Deloitte and Thomson Reuters. The Burrill Report spoke to Neil Lesser, principal of life sciences strategy for Deloitte, about the industry’s efforts to remake R&D, [...]

December 11, 2013 Andrea Hodgetts CASMI Views 0

FDA on Personalised Medicine

BioCentuary Personalised Medicine

Stratified Medicine (personalising treatments to distinct patient populations) is the topic of this week’s BioCentury videocast. The FDA recently approved Illumina’s Next Generation Sequencing Technology, which rapidly and affordably sequences a patient’s genome, allowing doctors to make tailored treatment decisions after a single test. Following this decision, FDA Commissioner Margaret [...]

November 25, 2013 Andrea Hodgetts CASMI Views 0

Cut EU Red Tape: Report from the Business Taskforce

cut EU red tape slider

CASMI contributed to the latest report from the Business Taskforce written for British Government, which calls for cutting red tape in clinical trials and making flexibilities in licensing more visible. This is particularly relevant for our Adaptive Licensing project, which uses existing legislation to grant patients earlier access to new medicines, [...]

October 17, 2013 Andrea Hodgetts CASMI Views 0

WEBCAST: The Current State of Biomedical Innovation

Screen Shot 2013-09-03 at 12.20.22

Summary from the Brookings Institution: On July 16, the Engelberg Center for Health Care Reform at Brookings hosted the second annual State of Biomedical Innovation conference. The goal of this conference was to assess U.S. biomedical innovation and discuss policy solutions that ensure the nation remains a world leader. This year, the conference [...]

September 3, 2013 Andrea Hodgetts CASMI Views 0

VIDEO: “The answer is not to stop innovating but to innovate better” – Sir John Tooke

JT Speech


August 27, 2013 Andrea Hodgetts CASMI Views 0